Market Overview

UPDATE: Piper Jaffray Raises PT on BioMarin Pharmaceutical on Positive Trial Results

Related BMRN
UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB

In a report published Wednesday, Piper Jaffray analyst M Ian Somaiya reiterated an Overweight rating on BioMarin Pharmaceutical (NASDAQ: BMRN), and raised the price target from $64.00 to $70.00.

In the report, Somaiya noted, “BioMarin announced positive results from POM-001, the Phase I/II trial of BMN-701 in Pompe disease and confirmed its intention to advance ‘701 into Phase II/III by YE13. Overall, we believe the data are positive, with patients achieving meaningful improvements in pulmonary function and greater proportion of super responders in 6MWD. However, we believe the bar for success was relatively low, given go/no-go criteria outlined on the 4Q call and Myozyme's modest efficacy. Additionally, we note some variability in the data including lack of change in select pulmonary function measures (FVC).”

BioMarin Pharmaceutical closed on Tuesday at $60.76.

Latest Ratings for BMRN

DateFirmActionFromTo
Dec 2014JP MorganMaintainsOverweight
Dec 2014UBSMaintainsBuy
Nov 2014JefferiesMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters